Organization | Ragon Institute of MGH, MIT and Harvard

Ragon Institute of MGH, MIT and Harvard Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Boston MA United States (2009)

Organization Overview

First Clinical Trial

2010

NCT01215149

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Ragon Institute | Ragon Institute of MGH, MIT and Harvard

Active Ingredients

Drugs in Phase 4 Trials (3)

abacavir (ziagen) (1 trial)

dolutegravir (tivicay) (1 trial)

lamivudine (epivir) (2 trials)

Drugs in Phase 3 Trials (3)

lopinavir (Kaletra) (1 trial)

nevirapine (viramune) (1 trial)

zidovudine (retrovir) (1 trial)

Drugs in Phase 2 Trials (1)

teduglutide (gattex kit) (1 trial)

Drugs in Phase 1 Trials (9)

3bnc117 (1 trial)

ad26.enva.01 vaccine (1 trial)

ad26.mos.hiv (1 trial)

ad35-env (1 trial)

clade c gp140 (1 trial)

mosaic gp140 env trimers (1 trial)

mva-mosaic (1 trial)

pgt121 (1 trial)

vrc-hivmab080-00-ab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acquired Immunodeficiency Syndrome (Phase 1)

HIV Infections (Phase 1)

Immunologic Deficiency Syndromes (Phase 1)

Inflammation (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 7
# of Trial APIs: 16